GlassScriptPhysician profile
Nina Phatak
NPI 1093828147
$4,335.88
in general payments reported to CMS, 2019-2025
30 companies · $736 in 2025
The $736 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $153 · 2021: $306 · 2022: $460 · 2023: $483 · 2024: $1,169 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,372 · Education: $16.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.76 |
| Education | $16.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,423.05 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $458.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $375.55 | 2019-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $347.29 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $201.81 | 2023-2025 | Tremfya, Stelara, Remicade |
| Madrigal Pharmaceuticals | $199.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $153.15 | 2019-2025 | |
| Celgene Corporation | $143.16 | 2023-2024 | Zeposia |
| Ethicon US, LLC | $130.30 | 2019-2024 | Linx Reflux Management System |
| Lilly USA, LLC | $107.51 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $106.92 | 2024 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.57 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $68.37 | 2024-2025 | Ibsrela |
| Ucb, INC. | $64.10 | 2019 | |
| Qol Medical, LLC | $58.45 | 2025 | Sucraid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $57.72 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $46.15 | 2025 | Voquezna |
| Celltrion USA INC. | $45.75 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $38.71 | 2019-2025 | |
| Medtronic, INC. | $35.05 | 2022-2023 | Hawkone |
| Glaukos Corporation | $30.39 | 2025 | Idosetr |
| Allergan, INC. | $25.67 | 2019-2020 | |
| Amgen INC. | $19.68 | 2020 | |
| Genzyme Corporation | $19.29 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.21 | 2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $18.50 | 2023 | Linzess |
| Merck Sharp & Dohme LLC | $18.41 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.91 | 2023 | Givlaari |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Phatak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.